Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes

NCT01113801 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01113801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01113801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2010
Completion date
July 31, 2014
Enrollment
417 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic glomerulosclerosis, diabetic kidney disease, diabetic nephropathy